API Import of Trypsinogen obtained from Indian Customs Trade Statistics

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Trypsinogen from bovine pancreas, 9002-08-8, Einecs 232-651-3, (2s,5s,8s,11s,14s)-2-(4-aminobutyl)-14-((s)-2-((s)-1-((s)-2-aminopropanoyl)pyrrolidine-2-carboxamido)-3-phenylpropanamido)-5,8,11-tris(carboxymethyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazahexadecane-1,16-dioic acid
Molecular Formula
C39H55N9O17
Molecular Weight
921.9  g/mol
InChI Key
NDIORHLFYZGYPG-FNRPHRCSSA-N

Trypsinogen
The inactive proenzyme of trypsin secreted by the pancreas, activated in the duodenum via cleavage by enteropeptidase. (Stedman, 25th ed)
1 2D Structure

Trypsinogen

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]hexanoic acid
2.1.2 InChI
InChI=1S/C39H55N9O17/c1-19(41)38(63)48-13-7-11-27(48)37(62)47-22(14-20-8-3-2-4-9-20)32(57)43-24(16-29(51)52)34(59)45-26(18-31(55)56)36(61)46-25(17-30(53)54)35(60)44-23(15-28(49)50)33(58)42-21(39(64)65)10-5-6-12-40/h2-4,8-9,19,21-27H,5-7,10-18,40-41H2,1H3,(H,42,58)(H,43,57)(H,44,60)(H,45,59)(H,46,61)(H,47,62)(H,49,50)(H,51,52)(H,53,54)(H,55,56)(H,64,65)/t19-,21-,22-,23-,24-,25-,26-,27-/m0/s1
2.1.3 InChI Key
NDIORHLFYZGYPG-FNRPHRCSSA-N
2.1.4 Canonical SMILES
CC(C(=O)N1CCCC1C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CC(=O)O)C(=O)NC(CC(=O)O)C(=O)NC(CC(=O)O)C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)O)N
2.1.5 Isomeric SMILES
C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N
2.2 Synonyms
2.2.1 MeSH Synonyms

1. Trypsinogen 1

2.2.2 Depositor-Supplied Synonyms

1. Trypsinogen From Bovine Pancreas

2. 9002-08-8

3. Einecs 232-651-3

4. (2s,5s,8s,11s,14s)-2-(4-aminobutyl)-14-((s)-2-((s)-1-((s)-2-aminopropanoyl)pyrrolidine-2-carboxamido)-3-phenylpropanamido)-5,8,11-tris(carboxymethyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazahexadecane-1,16-dioic Acid

2.3 Create Date
2015-11-11
3 Chemical and Physical Properties
Molecular Weight 921.9 g/mol
Molecular Formula C39H55N9O17
XLogP3-8.9
Hydrogen Bond Donor Count13
Hydrogen Bond Acceptor Count19
Rotatable Bond Count28
Exact Mass921.37159132 g/mol
Monoisotopic Mass921.37159132 g/mol
Topological Polar Surface Area433 Ų
Heavy Atom Count65
Formal Charge0
Complexity1770
Isotope Atom Count0
Defined Atom Stereocenter Count8
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Drugs in Development

read-more
read-more

Details:

PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.


Lead Product(s): Trypsinogen,Chymotrypsinogen

Therapeutic Area: Oncology Brand Name: PRP

Study Phase: PreclinicalProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 22, 2024

blank

01

Propanc Biopharma

Australia
arrow
ASC 2024
Not Confirmed

Propanc Biopharma

Australia
arrow
ASC 2024
Not Confirmed

Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.

Brand Name : PRP

Molecule Type : Large molecule

Upfront Cash : Not Applicable

February 22, 2024

blank

Details:

PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.


Lead Product(s): Trypsinogen,Chymotrypsinogen

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: PreclinicalProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 15, 2023

blank

02

Propanc Biopharma

Australia
arrow
ASC 2024
Not Confirmed

Propanc Biopharma

Australia
arrow
ASC 2024
Not Confirmed

Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.

Brand Name : Undisclosed

Molecule Type : Large molecule

Upfront Cash : Not Applicable

August 15, 2023

blank

Details:

PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.


Lead Product(s): Chymotrypsinogen,Trypsinogen

Therapeutic Area: Oncology Brand Name: PRP

Study Phase: Phase IProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 12, 2022

blank

03

Propanc Biopharma

Australia
arrow
ASC 2024
Not Confirmed

Propanc Biopharma

Australia
arrow
ASC 2024
Not Confirmed

Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.

Brand Name : PRP

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 12, 2022

blank

Details:

PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection for a method to treat cancer stem cells.


Lead Product(s): Chymotrypsinogen,Trypsinogen

Therapeutic Area: Oncology Brand Name: PRP

Study Phase: Phase IProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 16, 2022

blank

04

Propanc Biopharma

Australia
arrow
ASC 2024
Not Confirmed

Propanc Biopharma

Australia
arrow
ASC 2024
Not Confirmed

Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection for a method to treat cancer stem cells.

Brand Name : PRP

Molecule Type : Small molecule

Upfront Cash : Not Applicable

August 16, 2022

blank

Details:

PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection, in the treatment of cancer.


Lead Product(s): Chymotrypsinogen,Trypsinogen

Therapeutic Area: Oncology Brand Name: PRP

Study Phase: Phase IProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 12, 2022

blank

05

Propanc Biopharma

Australia
arrow
ASC 2024
Not Confirmed

Propanc Biopharma

Australia
arrow
ASC 2024
Not Confirmed

Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection, in the treatment of cancer.

Brand Name : PRP

Molecule Type : Large molecule

Upfront Cash : Not Applicable

July 12, 2022

blank

Details:

PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.


Lead Product(s): Chymotrypsinogen,Trypsinogen

Therapeutic Area: Oncology Brand Name: PRP

Study Phase: PreclinicalProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 05, 2022

blank

06

Propanc Biopharma

Australia
arrow
ASC 2024
Not Confirmed

Propanc Biopharma

Australia
arrow
ASC 2024
Not Confirmed

Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.

Brand Name : PRP

Molecule Type : Large molecule

Upfront Cash : Not Applicable

July 05, 2022

blank

Details:

PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.


Lead Product(s): Chymotrypsinogen,Trypsinogen

Therapeutic Area: Oncology Brand Name: PRP

Study Phase: PreclinicalProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2022

blank

07

Propanc Biopharma

Australia
arrow
ASC 2024
Not Confirmed

Propanc Biopharma

Australia
arrow
ASC 2024
Not Confirmed

Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.

Brand Name : PRP

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 22, 2022

blank

Details:

PRP is mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by IV injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.


Lead Product(s): Chymotrypsinogen,Trypsinogen

Therapeutic Area: Oncology Brand Name: PRP

Study Phase: Phase IProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 26, 2022

blank

08

Propanc Biopharma

Australia
arrow
ASC 2024
Not Confirmed

Propanc Biopharma

Australia
arrow
ASC 2024
Not Confirmed

Details : PRP is mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by IV injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.

Brand Name : PRP

Molecule Type : Large molecule

Upfront Cash : Not Applicable

May 26, 2022

blank

Details:

PRP (chymotrypsinogen) is the Company’s lead product candidate and is a novel pharmaceutical formulation consisting of two proenzymes to be administered by I.V. injection in a world first, First-In-Human (FIH) study in advanced cancer patients.


Lead Product(s): Chymotrypsinogen,Trypsinogen

Therapeutic Area: Oncology Brand Name: PRP

Study Phase: Phase IProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2022

blank

09

Propanc Biopharma

Australia
arrow
ASC 2024
Not Confirmed

Propanc Biopharma

Australia
arrow
ASC 2024
Not Confirmed

Details : PRP (chymotrypsinogen) is the Company’s lead product candidate and is a novel pharmaceutical formulation consisting of two proenzymes to be administered by I.V. injection in a world first, First-In-Human (FIH) study in advanced cancer patients.

Brand Name : PRP

Molecule Type : Large molecule

Upfront Cash : Not Applicable

May 18, 2022

blank

Details:

PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection, in advanced cancer patients suffering from solid tumors.


Lead Product(s): Chymotrypsinogen,Trypsinogen

Therapeutic Area: Oncology Brand Name: PRP

Study Phase: Phase IProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 02, 2022

blank

10

Propanc Biopharma

Australia
arrow
ASC 2024
Not Confirmed

Propanc Biopharma

Australia
arrow
ASC 2024
Not Confirmed

Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection, in advanced cancer patients suffering from solid tumors.

Brand Name : PRP

Molecule Type : Large molecule

Upfront Cash : Not Applicable

May 02, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty